01 abril 2012

JACC: CARDIOVASCULAR INTERVENTIONS. Risk Factors and Outcomes of Post-Procedure Heart Blocks After Transcatheter Device Closure of Perimembranous Ventricular Septal Defect

Rong Yang, MD; Xiang-Qing Kong, MD; Yan-Hui Sheng, MD; Lei Zhou, MD; Di Xu, MD; Yong-Hong Yong, MM; Wei Sun, MD; Hao Zhang, MD; Ke-Jiang Cao, MD

Objectives: The aim of this study was to analyze the risk factors and mid-term outcomes associated with post-procedure heart blocks (PPHBs) after transcatheter closure of perimembranous ventricular septal defect (pmVSD).

23 febrero 2010

JACC. The Risk of Thromboembolism and Need for Oral Anticoagulation After Successful Atrial Fibrillation Ablation

Sakis Themistoclakis, MD, Andrea Corrado, MD, Francis E. Marchlinski, MD, Pierre Jais, MD, Erica Zado, PAC, Antonio Rossillo, MD, Luigi Di Biase, MD, Robert A. Schweikert, MD, Walid I. Saliba, MD, Rodney Horton, MD, Prasant Mohanty, MBBS, MPH, Dimpi Patel, DO, David J. Burkhardt, MD, Oussama M. Wazni, MD, Aldo Bonso, MD, David J. Callans, MD, Michel Haissaguerre, MD, Antonio Raviele, MD, Andrea Natale, MD

Journal of the American College of The aim of this multicenter study was to evaluate the safety of discontinuing oral anticoagulation therapy (OAT) after apparently successful pulmonary vein isolation. Cardiology Vol. 55, No. 8, 2010. Copyright © 2010 by the American College of Cardiology Foundation ISSN: 0735-1097/10. Published by Elsevier Inc.

01 abril 2012

JACC: CARDIOVASCULAR INTERVENTIONS. Provoked Exercise Desaturation in Patent Foramen Ovale and Impact of Percutaneous Closure FREE

Ganesh P. Devendra, MD; Ajinkya A. Rane, BS; Richard A. Krasuski, MD

Objectives: This study was designed to assess the prevalence of provoked exercise desaturation (PED) in patients with patent foramen ovale (PFO) referred for cardiovascular evaluation and to evaluate the impact of PFO closure.

27 marzo 2012

ARCHIVES OF CARDIOVASCULAR DISEASE. Transcatheter aortic valve replacement: A breakthrough medical therapy! The 20-year odyssey, and now, a 10-year anniversary

Martin B. Leon Columbia University Medical Center, Center for Interventional Vascular Therapy, New York Presbyterian Hospital, 161, Fort Washington Avenue, 6th Floor, New York, NY 10032, United States

The concluding statement from a first-in-man case report published in Circulation in 2002 was: ‘‘Nonsurgical implantation of a prosthetic heart valve can be successfully achieved with immediate and midterm hemodynamic and clinical improvement’’ [1]. The lead author of this short manuscript was Alain Cribier, and the procedure involved transcatheter placement of a bioprosthetic aortic valve in a desperately ill man with critical aortic stenosis (AS) and no therapy alternatives. At the time, it was impossible to predict the future of this new medical therapy, which at the same time appeared both reckless and revolutionary. In retrospect, 10 years later, this humble concluding statement laid the foundation for a medical breakthrough that has altered the landscape of cardiovascular medicine. The odyssey and the anniversary of transcatheter aortic valve replacement (TAVR) deserve our attention and careful reflection. Archives of Cardiovascular Disease (2012) 105, 129—131. Copyright © 2012 Published by Elsevier Masson SAS.

06 febrero 2012

ARCHIVES OF CARDIOVASCULAR DISEASE. Transcatheter aortic valve implantation: Surgical perspectives

Thomas Walther, Jörg Kempfert, Friedrich W. Mohr

Aortic valve replacement (AVR) is a routine procedure for decades to treat patients with symptomatic aortic stenosis. The introduction of transcatheter aortic valve implantation (TAVI) by Professor Alain Cribier has paved the way for minimally invasive therapeutic options for elderly and high-risk patients with aortic stenosis. Transfemoral and transapical aortic valve implantations have become routine procedures in many centres around Europe. TAVI is usually being performed together by experienced cardiologists and cardiac surgeons who build the interdisciplinary ‘Heart Team’. In the future, improved devices together with advanced fusion imaging will lead to a further improvement in clinical outcomes for the sake of our patients. Archives of Cardiovascular Disease (2012) 105, 174—180 Copyright © 2012 Published by Elsevier Masson SAS.

01 febrero 2012

SOCIEDADE BRASILEIRA DE CARDIOLOGIA. Oclusión Percutánea de la Orejuela Auricular Izquierda con el Amplatzer Cardiac Plug™ en Fibrilación Auricular

Márcio José Montenegro, Edgard Freitas Quintella, Aníbal Damonte, Hugo de Castro Sabino, Ricardo Zajdenverg, Gustavo Pinaud Laufer, Bernardo Amorim, André Pereira Duque Estrada, Cristian Paul Yugcha Armas, Aline Sterque

La fibrilación auricular está asociada a accidentes vasculares de origen embólico que frecuentemente resultan en muerte o invalidez. Siendo eficaz en la reducción de esos eventos, la anticoagulación posee varias limitaciones y viene siendo ampliamente subutilizada. Más de 90% de los trombos identificados en los portadores de fibrilación auricular sin enfermedad valvular se originan en la orejuela auricular izquierda, cuya oclusión es investigada como una alternativa a la anticoagulación. Arq Bras Cardiol 2012;98(2):143-150.

01 enero 2012

YONSEI MEDICAL JOURNAL. Early Experience Using a Left Atrial Appendage Occlusion Device in Patients with Atrial Fibrillation

Yung Ly Kim, Boyoung Joung, Young Keun On, Chi Young Shim, Moon Hyoung Lee, Young-Hoon Kim, and Hui-Nam Pak

Atrial fibrillation (AF) is one of the major risk factors for ischemic stroke, and 90% of thromboembolisms in these patients arise from the left atrial appendage (LAA). Recently, it has been documented that an LAA occlusion device (OD) is not inferior to warfarin therapy, and that it reduces mortality and risk of stroke in patients with AF. Yonsei Med J 53(1):83-90, 2012. © Copyright: Yonsei University College of Medicine 2012

16 marzo 2011

JAMA. Standard vs High Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. The GRAVITAS Randomized Trial

Matthew J. Price, MD Peter B. Berger, MD Paul S. Teirstein, MD Jean-Franc¸ ois Tanguay, MD Dominick J. Angiolillo, MD Douglas Spriggs, MD Sanjeev Puri, MD Mark Robbins, MD Kirk N. Garratt, MD Olivier F. Bertrand, MD Michael E. Stillabower, MD Joseph R. Aragon, MD David E. Kandzari, MD Curtiss T. Stinis, MD Michael S. Lee, MD Steven V. Manoukian, MD Christopher P. Cannon, MD Nicholas J. Schork, PhD Eric J. Topol, MD for the GRAVITAS Investigators

Context High platelet reactivity while receiving clopidogrel has been linked to cardiovascular events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue is not well defined. Objective To evaluate the effect of high-dose compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity after PCI. Copyright © 2011 American Medical Association. All rights reserved. JAMA, March 16, 2011—Vol 305, No. 11

17 enero 2012

CIRCULATION. Bare Metal Stent Thrombosis and In-Stent Neoatherosclerosis

Original Articles Bare Metal Stent Thrombosis and In-Stent Neoatherosclerosis Kyohei Yamaji, MD, Katsumi Inoue, MD, Takuya Nakahashi, MD, Masahiko Noguchi, MD, Takenori Domei, MD, Makoto Hyodo, MD, Yoshimitsu Soga, MD, Shinichi Shirai, MD, Kenji Ando, MD, Katsuhiro Kondo, MD, Koyu Sakai, MD, Masashi Iwabuchi, MD, Hiroyoshi Yokoi, MD, Hideyuki Nosaka, MD, Masakiyo Nobuyoshi, MD and Takeshi Kimura, MD

Very late stent thrombosis (VLST) was reported to occur even in patients with bare metal stent (BMS) implantation, although the annual incidence of VLST after BMS was much lower than that after drug-eluting stent implantation. Pathophysiologic mechanisms of VLST after BMS implantation remain largely unknown. Copyright © 2012 American Heart Association. All rights reserved. Print ISSN: 1941-7640. Online ISSN:1941-7632

01 abril 2012

JACC: CARDIOVASCULAR INTERVENTIONS. Maximal Hyperemia in the Assessment of Fractional Flow Reserve

Antonio Maria Leone, MD, PhD; Italo Porto, MD, PhD; Alberto Ranieri De Caterina, MD; Eloisa Basile, MD; Andrea Aurelio, MD; Andrea Gardi, MS; Dolores Russo, MS; Domenico Laezza, RVT; Giampaolo Niccoli, MD, PhD; Francesco Burzotta, MD, PhD; Carlo Trani, MD; Mario Attilio Mazzari, MD; Rocco Mongiardo, MD; Antonio Giuseppe Rebuzzi, MD; Filippo Crea, MD

Objectives: This study sought to compare increasing doses of intracoronary (IC) adenosine or IC sodium nitroprusside versus intravenous (IV) adenosine for fractional flow reserve (FFR) assessment.

22 octubre 2010

EHJ. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies

Héctor Bueno, Amadeo Betriu, Magda Heras, Joaquín J. Alonso, Angel Cequier, Eulogio J. García, José L. López-Sendón, Carlos Macaya, and Rosana Hernández-Antolín, on behalf of the TRIANA Investigators

Aims: To compare primary percutaneous coronary intervention (pPCI) and fibrinolysis in very old patients with ST-segment elevation myocardial infarction (STEMI), in whom head-to-head comparisons between both strategies are scarce. Published on behalf of the European Society of Cardiology. European Heart Journal (2011) 32, 51–60. All rights reserved. Copyright The Author 2010.

17 mayo 2011

JACC. Incidence, Predictive Factors, and Prognostic Value of Myocardial Injury Following Uncomplicated Transcatheter Aortic Valve Implantation

Josep Rodés-Cabau, Marcos Gutiérrez, Rodrigo Bagur, Robert De Larochellière, Daniel Doyle, Mélanie Côté, Jacques Villeneuve, Olivier F. Bertrand, Eric Larose, Juan Manazzoni, Philippe Pibarot, and Eric Dumont

This study sought to: 1) determine the incidence, degree, and timing of the rise in serum cardiac markers of myocardial injury associated with uncomplicated transcatheter aortic valve implantation (TAVI); and 2) evaluate the predictive factors and prognostic value of myocardial injury associated with TAVI. Journal of the American College of Cardiology. Vol. 57, No. 20, 2011. Copyright © 2011 by the American College of Cardiology Foundation. Published by Elsevier Inc. ISSN 0735-1097.

22 marzo 2011

JACC. Incidence, Predictors, Treatment, and Long-Term Prognosis of Patients With Restenosis After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease

Jong-Young Lee, MD, Duk-Woo Park, MD, PHD, Young-Hak Kim, MD, PHD, Sung-Cheol Yun, PHD, Won-Jang Kim, MD, PHD, Soo-Jin Kang, MD, PHD, Seung-Whan Lee, MD, PHD, Cheol-Whan Lee, MD, PHD, Seong-Wook Park, MD, PHD, Seung-Jung Park, MD, PHD

The aim of this study was to evaluate the incidence, predictors, and long-term outcomes of patients with in-stent restenosis (ISR) after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for unprotected left main coronary artery (LMCA) disease. Journal of the American College of Cardiology. Vol. 57, No. 12, 2011. Copyright © 2011 by the American College of Cardiology Foundation. Published by Elsevier Inc. ISSN 0735-1097

19 abril 2011

JACC. The Acute Hemodynamic Effects of MitraClip Therapy

Robert J. Siegel, MD, Simon Biner, MD, Asim M. Rafique, MD, Michael Rinaldi, MD, Scott Lim, MD, Peter Fail, MD, James Hermiller, MD, Richard Smalling, MD, PHD, Patrick L. Whitlow, MD, Howard C. Herrmann, MD, Elyse Foster, MD, Ted Feldman, MD, Donald Glower, MD, Saibal Kar, MD, for the EVEREST Investigators

The objective of this study was to evaluate the acute hemodynamic consequences of mitral valve (MV) repair with the MitraClip device (Abbott Vascular, Menlo Park, California). Journal of the American College of Cardiology. Vol. 57, No. 16, 2011. Copyright © 2011 by the American College of Cardiology Foundation. Published by Elsevier Inc. ISSN 0735-1097.

19 abril 2011

JACC. 2-Year Follow-Up of Patients Undergoing Transcatheter Aortic Valve Implantation Using a Self-Expanding Valve Prosthesis

Lutz Buellesfeld, MD, Ulrich Gerckens, MD, Gerhard Schuler, MD, Raoul Bonan, MD, Jan Kovac, MD, Patrick W. Serruys, MD, Marino Labinaz, MD, Peter den Heijer, MD, Michael Mullen, MD, Wayne Tymchak, MD, Stephan Windecker, MD, Ralf Mueller, MD, Eberhard Grube, MD

The purpose of this study was to evaluate the safety, device performance, and clinical outcome up to 2 years for patients undergoing transcatheter aortic valve implantation (TAVI). Journal of the American College of Cardiology. Vol. 57, No. 16, 2011. Copyright © 2011 by the American College of Cardiology Foundation. Published by Elsevier Inc. ISSN 0735-1097